89bio
| General Information | |
| Business: |
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, is currently being developed for the treatment of NASH. NASH is a severe form of NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, HCC and death. There are currently no approved products for the treatment of NASH. FGF21 is a clinically-validated mechanism that has been shown in humans to reduce steatosis and address cardio-metabolic dysregulation. |
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 14 |
| Founded: | 2018 |
| Contact Information | |
| Address | 535 Mission Street, 14th Floor, San Francisco, CA 94105, US |
| Phone Number | (415) 500-4614 |
| Web Address | http://www.89bio.com |
| View Prospectus: | 89bio |
| Financial Information | |
| Market Cap | $207.9mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-28.2 mil (last 12 months) |
| IPO Profile | |
| Symbol | ETNB |
| Exchange | NASDAQ |
| Shares (millions): | 5.3 |
| Price range | $16.00 - $16.00 |
| Est. $ Volume | $84.9 mil |
| Manager / Joint Managers | BofA Securities/ SVB Leerink/ RBC Capital Markets |
| CO-Managers | Oppenheimer & Co. |
| Expected To Trade: | 11/11/2019 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |